Vnitřní lékařství 3/2021

PŘEHLEDOVÉ ČLÁNKY Léčba tří pacientů s Erdheimovou-Chesterovou chorobou kladribinem, případně kombinací kladribinu a cyklofosfamidu a přehled léčby této nemoci 164 | VNITŘNÍ LÉKAŘSTVÍ / Vnitř Lék 2021; 67(3): 157–164 / www.casopisvnitrnilekarstvi.cz 40. Tezol O, Citak EC, Ayhan YS et al. Effective High-dose Interferon-α Therapy in a 13-Ye- ar-Old Girl With Erdheim-Chester Disease. J Pediatr Hematol Oncol 2019. doi: 10.1097/ MPH.0000000000001538. 41. Aouba A, Georgin-Lavialle S, Pagnoux C et al. Rationale and efficacy of interleukin-1 targeting in Erdheim-Chester disease. Blood 2010; 116(20): 4070–4076. 42. Podestà MA, Graziani G, Reggiani F et al. Improvement of Erdheim-Chester disease-re- lated renal failure after treatment with anakinra. Kidney Res Clin Pract 2014; 33(3): 165–167. 43. Szturz P, Adam Z, Rehák Z et al. Xanthelasma palpebrarum responding to interleukin-1 blockade. Intern Med J 2014; 44(6): 617–618. 44. Darstein F, Kirschey S, Heckl S et al. Successful treatment of Erdheim-Chester disea- se with combination of interleukin-1-targeting drugs and high-dose glucocorticoids. In- tern Med J 2014; 44(1): 90–92. 45. Courcoul A, Vignot E, Chapurlat R. Successful treatment of Erdheim-Chester disease by interleukin-1 receptor antagonist protein. Joint Bone Spine 2014; 81(2): 175–177. 46. Killu AM, Liang JJ, Jaffe AS. Erdheim-Chester disease with cardiac involvement suc- cessfully treated with anakinra. Int J Cardiol 2013; 167(5): e115–117. 47. Aubert O, Aouba A, Deshayes S et al. Favorable radiological outcome of skeletal Erd- heim-Chester disease involvement with anakinra. Joint Bone Spine 2013; 80(2): 206–207. 48. Tran TA, Pariente D, Lecron JC et al. Treatment of pediatric Erdheim-Chester disease with interleukin-1-targeting drugs. Arthritis Rheum 2011; 63(12): 4031–4032. 49. Cohen-Aubart F, Maksud P, Saadoun D et al. Variability in the efficacy of the IL1 receptor antagonist anakinra for treating Erdheim-Chester disease. Blood 2016; 127(11): 1509–1512. 50. Goyal G, Shah MV, Call TG et al. Efficacy of biological agents in the treatment of Erd- heim-Chester disease. Br J Haematol. 2018; 183: 520–524. 51. Franconieri F, Deshayes S, de Boysson H et al. Superior efficacy and similar safety of double dose anakinra in Erdheim-Chester disease after single dose treatment. Oncoim- munology 2018; 7(8): e1450712. doi: 10.1080/2162402X.2018.1450712. 52. Dagna L, Corti A, Langheim S et al. Tumor necrosis factor α as a master regulator of inflammation in Erdheim-Chester disease: rationale for the treatment of patients with in- fliximab. J Clin Oncol 2012; 30(28): e286–e290. 53. Ferrero E, Belloni D, Corti A et al. TNF-alpha in Erdheim-Chester disease pericardial ef- fusion promotes endothelial leakage in vitro and is neutralized by infliximab. Rheumato- logy (Oxford). 2014; 53(1): 198–200. 54. Goyal G, Shah MV, Call TG et al. Efficacy of biological agents in the treatment of Erd- heim-Chester disease. Br J Haematol 2018; 183(3): 520–524. 55. Cohen-Aubart F, Maksud P, Emile J-F et al. Efficacy of infliximab in the treatment of Erdheim-Chester disease. Ann Rheum Dis 2018; 77: 1387–1390. 56. Jia X, Ning X, Bai Q et al. Combination of adalimumab with lower dose of methylpred- nisolone in Erdheim-Chester disease with systemic involvement. Acta Oncol. 2017; 56(5): 753–756. 57. Haroche J, Amoura Z, Charlotte F et al. Imatinib mesylate for platelet-derived growth factor receptor-beta-positive Erdheim-Chester histiocytosis. Blood 2008; 111(11): 5413–5415. 58. Montella L, Insabato L, Palmieri G. Imatinib mesylate for cerebral Langerhans’-cell his- tiocytosis. N Engl J Med 2004; 351(10): 1034–1035. 59. Utikal J, Ugurel S, Kurzen H et al. Imatinib as a treatment option for systemic non-Lan- gerhans cell histiocytoses. Arch Dermatol 2007; 143(6): 736–740. 60. Haroche J, Charlotte F, Arnaud L et al. High prevalence of BRAF V600E mutations inErd- heim-Chester disease but not in other non-Langerhans cell histiocytoses. Blood 2012; 27; 120(13): 2700–2703. 61. Haroche J, Cohen-Aubart F, Emile JF et al. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation. Blood 2013; 121(9): 1495–1500. 62. Hyman DM, Puzanov I, Subbiah V et al. Vemurafenib in multiple nonmelanoma can- cers with BRAF V600 mutations. N Engl J Med 2015; 373: 726–736. 63. Diamond EL, Durham BH, Haroche J et al. Diverse and targetable kinase alterations drive histiocytic neoplasms. Cancer Discov 2016; 6: 154–165. 64. Emile J-F, Diamond EL, Hélias-Rodzewicz Z et al. Recurrent RAS and PIK3CA mutations in Erdheim-Chester disease. Blood 2014; 124: 3016–3019. 65. Cohen-Aubart F, Emile JF, Maksud P et al. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease. Neurology 2014; 83(14): 1294–1296. 66. Diamond EL, Durham BH, Ulaner GA et al. Efficacy of MEK inhibition in patients with histiocytic neoplasms. Nature 2019; 567: 521–524. 67. Euskirchen P, Haroche J, Emile JF et al. Complete remission of critical neurohistiocyto- sis by vemurafenib. Neurol Neuroimmunol Neuroinflamm 2015; 2(2): e78. 68. Franconieri F, Martin-Silva N, de Boyssson H et al. A. Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies. Acta Oncol Acta Oncol. 2016; 55(7): 930–930. 69. Haroche J, Cohen-Aubart F, Emile JF et al. Reproducible and sustained efficacy of tar- geted therapy with vemurafenib in patients with BRAF(V600E)-mutated Erdheim-Ches- ter disease. J Clin Oncol 2015; 33(5): 411–4118. 70. Schirmer JH, Thorns C, Moosig F et al. Treatment failure by canakinumab in a patient with progressive multisystemic Erdheim-Chester disease refractory to anakinra: success- ful use of vemurafenib. Rheumatology (Oxford) 2015; 54(10): 1932–1934. 71. Tzoulis C, Schwarzlmüller T, Gjerde IO et al. Excellent response of intramedullary Erd- heim-Chester disease to vemurafenib: a case report. BMC Res Notes 2015; 8: 171. 72. Oneal PA, Kwitkowski V, Luo L e al. FDA Approval Summary: Vemurafenib for the Tre- atment of Patients with Erdheim-Chester Disease with the BRAFV600 Mutation. Oncolo- gist. 2018; 23(12): 1520–1524. 73. Diamond EL, Subbiah V, Lockhart AC et al. Vemurafenib for BRAF V600-mutant Erdheim-Chester disease and Langerhans cell histiocytosis: analysis of data from the histology-independent, phase 2, open-label VE-BASKET study. JAMA Oncol. 2018; 4: 384–388. 74. Cohen Aubart F, Emile J-F, Carrat F et al. Targeted therapies in 54 patients with Erd- heim-Chester disease, including follow-up after interruption (the LOVE study). Blood 2017; 130: 1377–1380. 75. Bhatia A, Hatzoglou V, Ulaner G et al. Neurologic and oncologic features of Erdheim- -Chester disease: a 30-patient series. Neuro Oncol 2020 Jan 17. pii: noaa008. doi: 10.1093/ neuonc/noaa008. 76. Grob JJ, Amonkar MM, Karaszewska B. Comparison of dabrafenib and trametinib com- bination therapy with vemurafenib monotherapy on health-related quality of life in pa- tients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive mela- noma (COMBI-v): results of a phase 3, open-label, randomised trial. Lancet Oncol 2015; 16(13): 1389–1398. 77. Al Bayati A, Plate T, Al Bayati M et al. Dabrafenib and Trametinib Treatment for Erd- heim-Chester Disease With Brain Stem Involvement. Mayo Clin Proc Innov Qual Outco- mes. 2018; 2(3): 303–308. 78. Sanders IM, Goodman A, Kurzrock R. Real word toxicity experience with BRAF/MEK in- hibitors in pacients with Erdheim-Chester disease. The Oncologist 2019; 24: 1–5. 79. Campochiaro C, Cavalli G, Farina N et al. Efficacy and improved tolerability of combina- tion therapy with interleukin-1 blockade and MAPK pathway inhibitors for the treatment of Erdheim-Chesterdisease. Ann Rheum Dis. 2019 Dec 9. pii: annrheumdis-2019-216610. doi: 10.1136/annrheumdis-2019-216610 80. Fernández-Eulate G, Muñoz-Lopetegi A, Ruiz I et al. Vemurafenib as first-line therapy in BRAF-V600E-mutant Erdheim-Chester disease with CNS involvement. BMJ Case Rep 2019; 12(11). pii: e228280. doi: 10.1136/bcr-2018-228280. 81. Van Keerberghen CA, Harrouk A, Leone L. A new role for fluorine-18-fluorodeoxyglu- cose positron-emission tomography/computed tomography in Erdheim-Chester disea- se. World J Nucl Med. 2019; 18(2): 201–203. 82. Akin EA, Osman M, Ellenbogen AL. FDG PET/CT Findings of Erdheim-Chester Di- sease: Radiologic Response to a Novel Treatment Regimen. Clin Nucl Med. 2018; 43(5): 337–340. 83. Young JR, Johnson GB, Murphy RC et al. (18)F-FDG PET/CT in Erdheim-Chester Disease: Imaging Findings and Potential BRAF Mutation Biomarker. J Nucl Med. 2018; 59(5): 774–779. 84. Rehák Z, Koukalová R, Vašina J et al. 18F-FDG PET/CT obraz Erdheimovy-Chesterovy nemoci – přehled českých pacientů. Nukl. Med. 20; 7: 50–56.